Bone Marrow Transplantation News

Use of subjective minimizing terminology, such as “safe” and “tolerable,” when discussing treatment-related toxicities occurs frequently at oncology and hematology conferences, according to a study published in Journal of Cancer Policy.

Allogeneic hematopoietic stem cell transplantation after CD19 chimeric antigen receptor T-cell therapy is thought to improve leukemia-free survival.

SAN DIEGO — The volume of hematopoietic stem cell transplantation procedures for advanced diffuse large B-cell lymphoma has declined precipitously since 2019, study results presented at ASH Annual Meeting and Exhibition showed.

The microbiome is linked to myriad processes in human health and disease.

This year’s ASH Annual Meeting featured several high-impact abstracts.

In this episode, host Shikha Jain, MD, speaks with St. Jude’s Steven Gottschalk, MD, and Paulina Velasquez, MD, about the evolution of bone marrow transplant and cell therapy, increasing accessibility to CAR T-cell therapy and more.

SAN DIEGO — Patients with relapsed large B-cell lymphoma who achieved a complete remission had a reduced relapse rate and improved PFS with autologous transplant, according to study findings presented at ASH Annual Meeting and Exposition.

Reduced-intensity haploidentical-bone marrow transplant showed durable donor engraftment at 2-years follow-up with low mortality among adults with severe sickle cell disease, according to study results.

SAN DIEGO — Axatilimab conferred clinically meaningful and durable responses at three dose levels among individuals with chronic graft-versus-host disease, randomized study results showed.

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 9-12 in San Diego.